Ophthalmic vascular manifestations in eosinophil-associated diseases: a comprehensive analysis of 57 patients from the CEREO and EESG networks and a literature review.

eosinophilia eosinophilic granulomatosis with polyangiitis hypereosinophilic syndrome optic neuropathy retinal artery occlusion retinal vasculitis retinal vein occlusion

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 31 01 2024
accepted: 04 04 2024
medline: 9 5 2024
pubmed: 9 5 2024
entrez: 9 5 2024
Statut: epublish

Résumé

Eosinophils have widespread procoagulant effects. In daily practice, eosinophil-related cardiovascular toxicity consists of endomyocardial damage, eosinophilic vasculitis and arterial or venous thrombosis. Here we aim to report on the clinical features and treatment outcomes of patients with unexplained ophthalmic vascular manifestations and eosinophilia. We conducted a retrospective, multicenter, observational study and a literature review of patients with eosinophilia (≥0.5 x10 Fifty-seven patients were included (20 from the observational study and 37 from the literature review). Ophthalmic vascular features were the initial manifestation of eosinophil-related disease in 34 (59%) patients and consisted of 29 central retinal artery occlusions, six branch retinal artery occlusions, five central retinal vein occlusions, two branch retinal vein occlusions, seven retinal vasculitides, two retinal vasospasms, 12 Purtscher's retinopathies, 13 anterior ischemic optic neuropathies and two posterior ischemic optic neuropathies. The median [IQR] absolute eosinophil count at onset of ophthalmic vascular manifestations was 3.5 [1.7-7.8] x10 This study broadens the spectrum of vascular manifestations associated with hypereosinophilia by adding ophthalmic vascular manifestations. In patients with ophthalmological vascular manifestations and hypereosinophilia, aggressive treatment of the underlying pathology (and normalization of blood count) should be implemented.

Identifiants

pubmed: 38720897
doi: 10.3389/fimmu.2024.1379611
pmc: PMC11078014
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't Review Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1379611

Informations de copyright

Copyright © 2024 Chapuis, Bousquet, Viallard, Terrier, Amoura, Batani, Brézin, Cacoub, Caminati, Chazal, Comarmond, Durieu, Ebbo, Grall, Ledoult, Losappio, Mattioli, Mékinian, Padoan, Regola, Schroeder, Seluk, Trefond, Wechsler, Lefevre, Kahn, Sève and Groh.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer AVM declared a shared parent affiliation with the author LL to the handling editor at the time of review.

Auteurs

Elisa Chapuis (E)

National Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Department of Internal Medicine, Bichat Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Elodie Bousquet (E)

Department of Ophthalmology, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Jean-François Viallard (JF)

National Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Department of Internal Medicine, Bordeaux University Hospital, Bordeaux, France.

Benjamin Terrier (B)

Department of Internal Medicine, National Referral Center for Systemic and Autoimmune Diseases, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Zahir Amoura (Z)

Department of Internal Medicine, Autoimmune and systemic diseases, La Pitié Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Veronica Batani (V)

Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.

Antoine Brézin (A)

Department of Ophthalmology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Patrice Cacoub (P)

Department of Internal Medicine and Clinical Immunology, La Pitié Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Marco Caminati (M)

Asthma Center and Allergy Unit, Center for Hyper-Eosinophilic Dysimmune Conditions, Department of Medicine, University of Verona, Verona, Italy.

Thibaud Chazal (T)

Department of Internal Medicine, Hospital Fondation Adolphe de Rothschild, Paris, France.

Cloé Comarmond (C)

Department of Internal Medicine, Competence Center for Rare Autoimmune and Inflammatory Diseases, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Isabelle Durieu (I)

Department of Internal Medicine, Centre Hospitalier Universitaire Lyon Sud, Pierre-Bénite, France.

Mikael Ebbo (M)

National Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Internal Medicine Department, Hopital La Timone, APHM, Aix Marseille University, Marseille, France.

Maximilien Grall (M)

Department of Internal Medicine, CHU Rouen, Rouen, France.

Emmanuel Ledoult (E)

National Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Department of Internal Medicine and Clinical Immunology, CHU Lille, Lille, France.

Laura Losappio (L)

Department of Clinical Immunology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Irene Mattioli (I)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Arsène Mékinian (A)

Department of Internal Medicine, St Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Roberto Padoan (R)

Unit of Rheumatology, Department of Medicine DIMED, University of Padua, Padua, Italy.

Francesca Regola (F)

Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy.

Jan Schroeder (J)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Lior Seluk (L)

Department of Medicine, National Jewish Health, Denver, CO, United States.

Ludovic Trefond (L)

National Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Michael E Wechsler (ME)

Department of Medicine, National Jewish Health, Denver, CO, United States.

Guillaume Lefevre (G)

National Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Inserm, U1286 - INFINITE - Institute for Translational Research in Inflammation, University of Lille, CHU Lille, Lille, France.

Jean-Emmanuel Kahn (JE)

National Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Department of Internal Medicine, Ambroise Pare Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne, France.

Pascal Sève (P)

Department of Internal Medicine, Lyon University Hospital, Lyon, France.

Matthieu Groh (M)

National Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Department of Internal Medicine, Foch Hospital, Suresnes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH